Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.

Abstract

BACKGROUND:

The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs; aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause impulse control disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs.

METHODS:

We downloaded and pre-processed the FDA Adverse Event Reporting System up to December 2020. We adapted Bradford Hill criteria to assess each TGA's -and secondarily other antipsychotics'-causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICD clinical features were analyzed, and their pathogenesis was investigated using receptor affinities.

RESULTS:

A total of 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% of cases. Frequently, co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-Hydroxytryptamine receptor type 1a agonism emerged as an additional plausible pathogenetic mechanism.

CONCLUSIONS:

We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior specific and may heavily impact on life. The role of 5-Hydroxytryptamine receptor type 1a agonism should be further explored.

• Authors: Michele Fusaroli, Emanuel Raschi, Valentina Giunchi, Marco Menchetti, Roberto Rimondini Giorgini, Fabrizio De Ponti, Elisabetta Poluzzi
• Journal: The international journal of neuropsychopharmacology (Int J Neuropsychopharmacol) Vol. 25 Issue 9 Pg. 727-736 (09 28 2022) ISSN: 1469-5111 [Electronic] England
• PMID: 35639870 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of CINP.

Chemical References

• Antipsychotic Agents
• Dopamine Agonists
• Quinolones
• Receptors, Serotonin
• Thiophenes
• brexpiprazole
• Aripiprazole
• Olanzapine
• Lurasidone Hydrochloride
• Dopamine

Topics

• Antipsychotic Agents (adverse effects)
• Aripiprazole (adverse effects)
• Disruptive, Impulse Control, and Conduct Disorders (chemically induced)
• Dopamine
• Dopamine Agonists (adverse effects)
• Humans
• Hyperphagia (chemically induced, drug therapy)
• Lurasidone Hydrochloride
• Olanzapine
• Pharmacovigilance
• Quinolones
• Receptors, Serotonin
• Thiophenes
• United States
• United States Food and Drug Administration